Mr. Speaker, I remember when OxyContin was first prescribed in Ontario. At the time it was supposed to be a miracle drug because it was not supposed to be addictive. We found that it was heavily over-prescribed, leading to all manner of problems in the general community. In my region, people who would never become addicted to opiates or that were given OxyContin without explanation of the effects. It raises the question of optimal prescribing practices and the need to work with the medical community to ensure that when doctors are given new medicines on the market that the issue of side effects and the implications of those drugs are properly explained.
The Canadian Agency for Drugs and Technologies in Health currently operates the optimal use program. It produces clinical guidelines and disseminates them to physicians, but it seems that there is an insufficient relationship between the impact of drugs and how this is being explained to physicians.
Given my hon. colleague's experience in the medical community, what does she think we need to do to ensure that when drugs are brought onto the market the issue of side effects and implications of those drugs are properly given to physicians on the front line?